BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$16.86 USD
-0.33 (-1.92%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $16.83 -0.03 (-0.18%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.86 USD
-0.33 (-1.92%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $16.83 -0.03 (-0.18%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth F Momentum C VGM
Zacks News
Boston Scientific (BSX) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for October 9th
by Zacks Equity Research
BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.
New Strong Sell Stocks for September 13th
by Zacks Equity Research
BLFS, ALCO and AFCG have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2023.
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Stryker (SYK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 6.72% and 3.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -60% and 12.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 13.95% and 7.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Rises 9.7% in a Year: More Room for Growth?
by Zacks Equity Research
Humana's (HUM) individual Medicare Advantage membership growth is likely to boost premium income.
Encompass Health's (EHC) 155th Hospital Opens in Wisconsin
by Zacks Equity Research
The Rehabilitation Hospital of Western Wisconsin is Encompass Health's (EHC) first location in the state.
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how BioLife Solutions, Inc. (BLFS) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
UnitedHealth (UNH) Plan in Indiana to Offer Pathways Program
by Zacks Equity Research
UnitedHealth (UNH) expects the new Pathways for Aging program to serve around 100,000 people.
Brookdale Senior (BKD) February Weighted Average Occupancy Up
by Zacks Equity Research
Brookdale Senior Living (BKD) witnesses 16 straight months of year-over-year increases in weighted average occupancy level.
Community Health (CYH) to Divest Two NC Hospitals for $320M
by Zacks Equity Research
Community Health (CYH) expects the North Carolina hospitals' divestment to close at a later part of this year.
Humana (HUM), CD&R Backed Gentiva to Buy Assets From ProMedica
by Zacks Equity Research
The acquisition is expected to boost Humana (HUM) and CD&R backed Gentiva's reach to over 500 locations.
Acadia Healthcare (ACHC) Q4 Earnings Miss on Rising Costs
by Zacks Equity Research
Acadia Healthcare's (ACHC) 2023 capital expenditure for expansion initiatives is predicted to stay between $350 million and $400 million.
Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SurModics (SRDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
SurModics (SRDX) delivered earnings and revenue surprises of 12.82% and 2.46%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 30% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
NuVasive (NUVA) delivered earnings and revenue surprises of 42.11% and 4.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for May 2nd
by Zacks Equity Research
ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022
New Strong Sell Stocks for March 31st
by Zacks Equity Research
BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.
BioLife Solutions, Inc. (BLFS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -131.25% and 0.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?